03 Jan 2012
(MENAFN) Gulf Pharmaceutical Industries (Julphar) said that commercial output of insulin at the firm’s new factory in Ras Al Khaimah (RAK) would be expected to start in 2012’s first quarter, reported The National.
The firm added that the USD136.1 million plant, which the company began to establish in the summer, has an annual output capacity of producing more than 50 million vials of insulin.
It also said that the firm would reduce the cost of insulin to the increasing number of diabetics in the region by manufacturing the drug locally, pointing out that nearly 90 percent of pharmaceuticals in the UAE are imported.
It is worth noting that Julphar’s sales in 2011 surpassed USD272.2, with total revenues up 11.3 percent to USD278 million.
01 Mar 2026
BBK activates partial remote working system for its workforce to ensure employee and customer safety and service continuity
24 Feb 2026
BBK discloses its financial results for the year ended 31st December 2025
05 Feb 2026
BBK announces December Al Hayrat Grand Prize winners and another wave of Grand prizes for February
26 Jan 2026
BBK Enhances Autumn Fair 2026 Experience with Customized Rewards and Premium Services
This website uses cookies to ensure you get the best experience and by clicking “I Accept” below, you consent to the use of cookies. Learn more